Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Paulina Karam

Clinical Nurse Specialist, Adult Health Oklahoma City, OK Nurse Practitioner

NPI 1710619911 CMS profile 11373712

825 Ne 10Th St, Oklahoma City, OK 73104

Open in the dashboard

General payments

$779

37 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paulina Karam of Oklahoma City, OK is reported in the CMS Open Payments database as having received $779 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $301 14
2024 General $310 15
2023 General $167 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paulina Karam
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Paulina Karam were reported at $301. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Paulina Karam Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $48–$445 $132
2022 $0 $163 $57–$526 $149
2023 $167 $173 $64–$597 $160
2024 $310 $171 $54–$575 $164
2025 $301 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Novartis Pharmaceuticals Corporation $257 12 payments
  2. E.R. Squibb & Sons, L.L.C. $199 11 payments
  3. Pulmonx Corporation $79 2 payments
  4. Kestra Medical Technology Services, Inc. $59 3 payments
  5. Baxter Healthcare $42 2 payments
  6. AstraZeneca Pharmaceuticals LP $29 1 payment
  7. Alnylam Pharmaceuticals Inc. $29 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $23 1 payment
  9. Janssen Pharmaceuticals, Inc $20 1 payment
  10. Stryker Corporation $15 1 payment
  11. Other $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $779 37 payments
Products named General payments · program years 2023–2025
  1. ENTRESTO $233 11 payments
  2. LEQVIO $205 9 payments
  3. CAMZYOS $184 10 payments
  4. CHARTIS CATHETER $79 2 payments
  5. ZEPHYR DELIVERY CATHETER $79 2 payments
  6. ZEPHYR ENDOBRONCHIAL VALVE $79 2 payments
  7. PULMONX CHARTIS TABLET CONSOLE $79 2 payments
  8. Assure WCD $59 3 payments
  9. Hillrom - Carnation Ambulatory Monitor $42 2 payments
  10. WAINUA $29 1 payment
  11. Other $143 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

288

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$96,830

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

39.6%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 39 $40,040
Jardiance Empagliflozin Brand 28 $25,374
Wegovy Semaglutide Brand 12 $15,221
Eliquis Apixaban Brand 22 $13,537
Dofetilide Generic 28 $1,199
Torsemide Generic 13 $438
Metoprolol Succinate Generic 33 $416
Diltiazem 24hr Er Diltiazem Hcl Brand 13 $237
Spironolactone Generic 32 $100
Warfarin Sodium Generic 26 $99

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $106
$106 39 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $54
$54 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $29
$29 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record